Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alteration.~* Measurable disease according to RECIST version 1.1.~* Prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational drugs.~* Prior radiotherapy is allowed~* Patients with controlled asymptomatic central nervous system involvement are allowed.~* Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.~* Adult patients age 18 years or older.~* Life expectancy of at least 3 months.~Key Exclusion Criteria:~* Current participation in another therapeutic clinical trial.~* Prior treatment with entrectinib.~* History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval \> 450 milliseconds).~* History of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome).~* Known active infections (bacterial, fungal, viral including HIV positivity).~* Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.~* Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis.~* Peripheral neuropathy ≥ Grade 2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Entrectinib (RXDX-101) (Type: EXPERIMENTAL): Oral entrectinib (RXDX-101)

Based on this trial design, predict the completion outcome and termination type (if applicable).